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Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is a new type of coronavirus that 
causes pneumonia. The clinical severity of COVID-19 is related to the presence of a cytokine storm 
that causes overproduction of inflammatory mediators such as interleukin (IL)-6. Tocilizumab (TCZ), 
as an IL-6 inhibitor, is the subject of major studies as a potential therapeutic agent. This study reported 
20 cases of COVID-19 patients being treated with the IL-6 inhibitor TCZ besides standard therapy. 
Patients were followed up on clinical, laboratory, and chest x-rays before and after the therapy 
administration, which was report descriptively. The oxygen saturation of patients who survived shows 
rapid improvements. The laboratory results showed that CRP decreased after administration TCZ 
immediately. Meanwhile, other markers improve slowly, such as leucocytes, Neutrophil Lymphocyte 
Ratio (NLR), Absolute Lymphocyte Count (ALC), and Lactate Dehydrogenase (LDH), but ferritin 
was tended to fluctuate. In chest X-rays, infiltrate bilateral on admission began to diminish until almost 
disappeared on the 14th day after TCZ. From 20 patients, 80% of patients survived with improvement 
in clinical, laboratory, and chest X-rays. At the same time, the rest death with a good response on the 
first therapy but fluctuated and worsened before death. Tocilizumab can be considered to provide 
clinical improvements in severe and critical COVID-19 patients. 
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INTRODUCTION 
Severe Acute Respiratory Syndrome 
Coronavirus 2 (SARS-CoV-2) is a new type 
of coronavirus that causes pneumonia, first 
reported in Wuhan, China, on December 31, 
2019.1 Analysis from the isolation of the 
lower respiratory tract shows a new type of 
coronavirus, which is named Coronavirus 
disease 2019 (COVID-19) by the World 
Health Organization (WHO). The coronavirus 
is the etiology of COVID-19, belongs to the 
genus betacoronavirus, round with some 
pleomorphic shape, and 60-140 nm in 
diameter. The results of phylogenetic analysis 
show that this virus in the same subgenus as 
the coronavirus caused the SARS outbreak in 
2002-2004, namely Sarbecovirus. The 
International Committee on Taxonomy of 
Viruses (ICTV) named the cause of COVID-
19 as SARS-CoV-2.2 
On May 03, 2021, WHO recorded 152 
million confirmed cases of COVID-19, with 
3,1 thousand confirmed deaths people 
worldwide. In Indonesia, statistical data as of 
May 2021 1,691,658 cases with 46,349 
deaths.  As one of the provinces in Indonesia, 
South Kalimantan reports the number of 
confirmed positive cases of 33,148 and 995 
cases of death. 1,3 
The clinical severity of COVID-19 is 
related to the presence of a "cytokine storm" 
that causes the overproduction of 
inflammatory mediators. The great majority 
of the inflammatory cells infiltrating the lungs 
are monocytes and macrophages. When 
COVID-19 infection, monocytes, and 
macrophages are increased, which may 
explain elevated levels of pro-inflammatory 
cytokines such as interleukin (IL)-6, IL-1, 
tumor necrosis factor (TNF)α, and IL-8, 
which in some patients turn out to be a 
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cytokine storm. 4 In particular, IL-6 emerged 
as a treatment target because of its strong 
association with disease severity. IL-6 more 
than 55 pg/mL resulted in a high risk of severe 
COVID-19. Meanwhile, the cut-off value of 
more than 80 pg/ml is related to patient 
mortality. 5  
The current treatment of COVID-19 is 
supportive therapy, and there is no definite 
clinical trial data that support preventive or 
therapeutic drugs. Current management 
guidelines in various countries rely to a large 
extent on some evidence from small studies or 
an interim analysis. Tocilizumab (TCZ) is an 
example of an IL-6 inhibitor, which is 
currently the subject of major studies besides 
sarilumab, siltuximab, and clazakizumab. The 
drug is currently considered one of the 
additional immunomodulatory therapies that 
can benefit in severe or critical COVID-19. 6 
The use of tocilizumab has been studied 
in several other places: China, Italy, France, 
Qatar, and the USA. Most of them provided a 
fairly good clinical improvement for people 
with COVID-19. Some showed less 
significant changes.7 However, considering 
the variants of COVID-19 that vary in several 
places and there are many differences such as 
race, ethnicity, and geography in various 
research subjects may give different results.8,9 
Meanwhile, research in Indonesia on the use 
of this drug is still limited. 
The inflammatory response that occurs 
due to COVID-19 infection can be observed 
indirectly with inflammatory markers such as 
C-Reactive Protein (CRP), Lactate 
Dehydrogenase (LDH), and Ferritin reported 
to increase in cases of COVID-19. In addition, 
it can also be observed from the body's 
immune response, such as the number of 
leucocytes, Neutrophil Lymphocyte Ratio 
(NLR), and Absolute Lymphocyte Count 
(ALC). 10 
Case reports in two moderate to severe 
COVID-19 patients showed satisfactory 
results with the administration of TCZ. 
Studies of COVID-19 patients in China also 
show that TCZ is an effective therapy in 
severe and critical COVID-19 COVID-19 
patients. In a retrospective study in 51 
COVID-19 patients, TCZ was associated with 
a significantly shorter duration of vasopressor 
administration than in patients not given TCZ. 
11,12 This study will report the clinical features 
of 20 severe and critical patients with 
confirmed COVID-19 who were given TCZ 
as an additional therapy. 
 
MATERIAL AND METHODS 
This case study is from the medical 
records of 20 COVID-19 confirmed patients 
treated in the Ulin General Hospital 
Banjarmasin isolation room with a severe-
critical case and received TCZ besides 
standard therapy from Mei to September 
2020. A confirmed case of COVID-19 was 
defined by a positive result on a reverse-
transcriptase–polymerase-chain-reaction 
(RT-PCR) assay of a specimen collected on a 
nasopharyngeal swab.  Severe cases are 
defined as dyspnea, respiratory frequency ≥ 
30 breaths/minute, oxygen saturation [SpO2] 
≤ 93%, and critical case are defined as acute 
respiratory distress syndrome, septic shock, 
and multiorgan dysfunction or failure.  
Descriptive statistics were used in this 
study to summarize data and results reported 
in median and interquartile ranges where 
appropriate. Categorical variables were 
summarized as counts and percentages. No 
imputations are made for the lost data. Data 
were processed and illustrated using Graphs 
with GraphPad Prism 8.0.1.  
 
RESULTS 
Demographic and Clinical Characteristic 
In this case, we provide TCZ adjunct 
therapy to patients with severe and critical 
conditions. The median age of this report was 
50 (26-70) years. Patients were male 70%, 
with 55% obese and 30% overweight. A 
history of smoking was found in 3 of 20 cases 
(15%). The patient's previous medical history 
was hypertension (25%) and diabetes mellitus 
(25%). The initial complaints experienced by 
most patients were shortness of breath (95%), 
cough (90%), and fever (85%). The length of 
admission days from a patient hospitalized 
until reverse transcriptase-polymerase chain 
reaction (RT-PCR) result negative or death 
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was between 20-57 days with a median of 
28.5 days (Table 1). 
 
Table 1. Baseline Demographic and Clinical Manifestation of COVID-19 Patients 
Variable N % 
Age in years, median (range) 50 (26-70)   
Gender     
Male 14 70.0 
Female 6 30.0 
Body Mass Index     
Normal (18,5-25) 3 15.0 
Overweight (25,1-27) 6 30.0 
Obesity (>27)  11 55.0 
History of Smoking 3 15.0 
Comorbidities     
Diabetes Mellitus 5 25.0 
Hypertension  5 25.0 
Clinical Manifestation     
Fever/ History of Fever 16 85.0 
Shortness of Breath 19 95.0 
Cough 18 90.0 
Sore Throat  1 5.0 
Cold 2 10 
Anosmia 2 10 
Nausea/ Vomiting  6 30 
Diarrhea 4 20 
Fatigue 6 30 
Admission days, median (range) 28,5 (20-57)   
 
The development of oxygen saturation 
(SpO2) of 20 patients in this report is shown 
in Figure 1. In the survivor group (figure 1A), 
the SpO2 of 16 patients varied from 70% 
before TCZ. It can be seen that the 
improvement of oxygen saturation and more 
homogeneous in all patients until day 14 after 
administration of TCZ, which is all the 
oxygen saturation is 95% and above. Oxygen 
saturation increased in the first days after the 
treatment with tocilizumab and returned to 
normal in most of the patients who survived 
on the 11th day.  
Meanwhile, in the four patients who died 
(Figure 1B), all the oxygen saturation before 
therapy was below 90%, then increased on the 
first days but fluctuated after that. On the first 
to the third day, there was a good response 
which the increase of saturation then 
fluctuated and experienced a gradual decrease 
until death.   
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Figure 1. Oxygen saturation in survivor (A) and non-survivor (B) patients before and after TCZ 
administration. (A) Oxygen saturation increased in the first days after the treatment with tocilizumab 
and returned to normal in most patients. (B)  Oxygen saturation increased in the first days after TCZ 
but fluctuated on third days until it decreased near death. 
 
Laboratory Findings  
The laboratory results were presented in 
median and interquartile (Table 2) to assess 
their overall progress in all patients. From 
routine blood tests on leucocytes and different 
counts of leucocytes, we found that 
leucocytosis appears before TCZ 
administration (Figure 2A). The incidence of 
leucocytosis was common and generally 
stable until the 8th day. On the 12th and 14th 
days, the median leucocytes values tended to 
fall to the normal range.  The NLR value 
(Figure 2B) gradually decreased on the fifth 
day of TCZ administration. 
Lymphocytopenia (Figure 2C), in which 
ALC obtained less than 1500/ µL, is common 
in patients in this study. Since the fifth day of 
TCZ administration, the ALC value showed 
fluctuation tended to increase until the 14th 
day. LDH (Figure 2D) fluctuated until five 
days of therapy, then gradually decreased 
from 8th to 14th after TCZ administration. CRP 
(Figure 2E) values were decreased since the 
third day of TCZ administration and continue 
to improve. Ferritin (Figure 2F) shows a 
change in the median ferritin value after three 
days of therapy, then fluctuated. 
 
Table 2. Laboratory Findings of COVID-19 Patients Before and After TCZ 
Variable Before TCZ Day-3 Day-5 Day-8 Day-12 Day-14 
 Median (IQR) 
Leucocytes, × 
109/L  
10.65 (8.45) 10.4 (8.93) 10.35 (8.975) 9.9 (12.28) 8.7 (18.6) 7.2 (14) 
NLR 6.97 (6.507) 7 (9.4) 5.63 (11.5) 5.9 (10.867) 2.92 (6.16) 2.5 (8.04) 
ALC 1027 (923) 1003 (1011.7) 1473 (1126.8) 1570 (834.6) 1459 (1060) 1539 (1003) 
LDH, U/L 641.5 (326) 569.5 (835.5) 692 (584) 515 (662) 256.5 (140.2) 247 (300) 
CRP, mg/dl 92.4 (131.05) 9.2 (50.1) 3.95 (11.45) 2.8 (7.225) 1.2 (8) 3.95 (7.725) 






























SpO2 in Survivor Group
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Figure 2. The values of leucocytes(A), NLR (B), 
ALC(C), LDH (D), CRP (E), and Ferritin (F) before and after the treatment with tocilizumab in 
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Chest X-rays 
All cases in this study had abnormal chest 
X-rays (CXR), ranging from minimal 
consolidation to the typical ground-glass-
opacity, common in pneumonia COVID-19. 
Below is attached a case with good progress 
before and after IL-6 inhibitor therapy (Figure 
3). Before administering therapy, a chest X-
ray of the patient with infiltrating bilateral 
began to diminish on the 7th day after therapy 




A. CXR before TCZ 
 
B. CXR 7th days  after TCZ  
 
C. CXR 14th days after TCZ 
 
Figure 3. Chest X Rays (A) infiltrate (arrows) bilateral before TCZ, (B) infiltrate (arrows) began to 




We studied 20 patients administered TCZ 
according to the standard of therapy. 
Currently, criteria for ideal candidates for IL-
6 therapy have not been agreed upon. In 
general, in the case series by Xu et al., the 
criteria for patients who can be candidates for 
IL-6 inhibitor therapy  as follows:11 
• Severe pneumonia, with hypoxemia, 
SpO2 <94% in room air, tachypnea (RR> 
30 x/m) or PaO2 / FiO2 ratio <300. 
• Critical pneumonia, i.e., patients require 
assisted mechanical ventilation or in 
shock and multiorgan failure requiring 
ICU care. 
Based on the above, all of the patients in 
this study were included in the criteria for a 
candidate. All of the patients in this study 
could be given IL-6 inhibitor therapy. In this 
study, we conducted observations on clinical 
symptoms such as peripheral oxygen 
saturation and laboratory markers of 
inflammation which are based on the 
literature associated with cytokine storms, 
namely leucocytes, NLR, ALC, LDH, CRP, 
and ferritin. The outcome of this study was the 
patient's status at the end of treatment died or 
experienced clinical improvement with 
reverse transcriptase-polymerase chain 
reaction (RT-PCR) result negative. 
Oxygen saturation is an observable 
feature of clinical improvement. In this study, 
there was an increase in SpO2 since the start 
of therapy. The SpO2 increase continued to 
improve, especially in survivor patients. 
Otherwise, in the dead patient, fluctuating and 
worsening happen since the third day. This 
assessment of SpO2 is important to see and 
assess the response after TCZ administration. 
When there is a worsening condition, the 
doctor must understand the direction of the 
disease progression and explore other 
possible causes of worsening in the patient's 
condition. 
The results of this study are in line with 
Xiaoling Xu et al. at Anhui Provincial 
Hospital, China, about the effective treatment 
of COVID-19 with TCZ.  They also reported 
15 patients (75%) have significant 
improvement in patients' peripheral oxygen 
saturation after TCZ administration within the 
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fifth day.13  Similar results were found in a 
randomized, double-blind, placebo-controlled 
trial conducted by J.H Stone et al. at Boston 
Hospital. The median time of discontinuation 
of supplemental oxygen in patients with TCZ 
was five days (Interquartile range 3.8-7.6). 
Although it was mentioned not significantly 
different from the placebo group. 14 
From routine blood tests on leucocytes 
and different counts of leucocytes, we found a 
slow improvement. Leucocyte decreased on 
8th days while NLR and ALC improve on 5th 
days.  COVID-19 infection activates both the 
immediate and adaptive immune systems. In 
conditions of increased inflammation, there 
will be an increase in the number of 
leukocytes and neutrophils and a decrease in 
the number of lymphocytes. 
Lymphocytopenia is currently a predictor that 
can be used to assess patient outcome. 15–17. 
The mechanisms underlying 
lymphocytopenia are unclear. Previous 
reports explained that several other viruses, 
such as dengue and SARS-CoV, infect cells 
through antibody-dependent enhancement 
(ADE), where the virus infects cells via IgG 
Fc or complement receptors. However, 
whether lymphocytopenia is associated with 
this severity in relation to ADE still needs 
further research. 18 
Lactate dehydrogenase (LDH) is one of 
the inflammation markers, and its values 
fluctuated until five days of therapy, then 
gradually decreased on the 8th to 14th after 
TCZ administration. Another study described 
that LDH values decreased in the first 24 
hours after TCZ then fluctuated until the 
seventh day. 19 LDH is one of the predictors 
of inflammation, where in previous studies, it 
was shown to be one of the predictors of 
outcomes with Area Under the Curve (AUC) 
of  0.878, and the cut-off value was 344.5. 20 
This LDH indicates tissue damage in patients, 
and it becomes a marker of inflammation. 
LDH was said to increase during acute and 
severe lung damage, and this increase in LDH 
has also been associated with other interstitial 
pulmonary infections. 21,22 
CRP values were conclusively 
significantly decreased since the third day of 
TCZ administration from a fairly extreme 
CRP rate in this study. In accordance with the 
target of action of TCZ as an IL-6 inhibitor 
which is directly related to CRP synthesis. IL-
6 is reported to be the main inducer of CRP 
gene expression, with IL-1 enhancing the 
effect. However, although IL-6 is necessary 
for CRP gene induction, it is insufficient to 
achieve this alone. Many factors can change 
the baseline CRP level, including age, gender, 
smoking status, body weight, lipid levels, and 
blood pressure. 23  
Therefore, the effect of TCZ 
administration on CRP can be seen more 
directly than other markers of inflammation. 
This is comparable to several studies in other 
countries. Research by Xioling Xu et al. also 
assessed the markers of inflammation after 
TCZ administration, showed a trend of 
marker improvement, and occurred rapidly on 
days 2-3.13 The research results by Keske et 
al. also showed an improvement in 
inflammatory markers after TCZ 
administration, which occurred more quickly 
two days post-therapy. 24 The results, which 
are not much different from those in China, 
may be due to research by Ansori et al. 
showing that there is no significant difference 
between the SARS-CoV-2 spike glycoprotein 
gene sequences found in Indonesia and the 
Wuhan-Hu-1 isolate from China. However, 
this is a preliminary study that may differ as 
the pandemic progresses.25 In previous 
studies, it was mentioned that CRP was one of 
the markers related to outcomes. 26, 
interestingly, TCZ decreases CRP and CRP 
related to prognosis, which can have an 
impact on outcomes.   
But, these results and virulence of 
COVID-19 are influenced by several factors 
such as host, agent, and environmental 
factors. The number of different variants of 
COVID-19 in various regions has recently 
been one of the influencing factors. 8 Several 
studies have also shown differences in host 
factors, such as finding differences in race, 
ethnicity, and geography. 9 Some have linked 
this with the differences in the SARS-CoV-2 
receptor mentioned. Even though 
Angiotensin-converting enzyme (ACE)2 is 
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expressed, it turns out that this virus cannot 
always use it as a receptor. The ability of 
SARS-CoV-2 to utilize ACE2 was predicted 
by observing a few essential single amino acid 
(A.A.) variant sites.27 
In ferritin, we found a change in the 
median ferritin value that has fluctuated. 
However, the distribution was tended not to 
have a difference. It should be noted that the 
result at our center of ferritin value is 
presented with a relatively small number of 
samples.  Comparable to other studies that 
showed fluctuating changes in ferritin until 
the seventh day after TCZ administration. 19 
Ferritin and IL-6 also showed higher values in 
the group with death. 28 During inflammation, 
ferritin is actively produced. Macrophages are 
thought to be responsible for ferritin 
secretion, which produces cytokines and 
immune cells in the lung parenchyma. Ferritin 
synthesis can also be induced by cytokines 
such as interleukin-6. Tocilizumab is an IL-6 
inhibitor agent that may affect ferritin changes 
as well. 29  
From 20 patients, 20% of patients in this 
study died, and 80% experienced 
improvement. An oxygen saturation 
improvement, an increase in ALC, and a 
decrease in CRP are markers that appear to 
have changed after the administration of TCZ 
therapy. Other laboratories had changed, but 
during the 14-day observation, they were 
fluctuated until showing improvement. 
This post-therapy improvement was 
related to the mechanism of infection SARS-
CoV-2 causing COVID-19 triggers a 
hyperinflammatory state driven by multiple 
cells and mediators such as interleukin (IL)-1, 
IL-6, IL-12, and IL-18, tumor-necrosis- 
factor-alpha (TNFα), etc. which cause a state 
called a cytokine storm. Cytokine storms 
cause ARDS and multiple organ failure, 
resulting from macrophage activating 
syndrome (MAS) in both sepsis and COVID-
19. This condition can be observed directly by 
examining the plasma IL-6 levels as one of the 
potent cytokines that cause cytokine storms. 
30–32 
In addition, the work of TCZ as an IL-6 
inhibitor is considered to be one of the 
therapeutic targets of the cytokine storm 
mechanism that occurs in severe and critical 
COVID-19 patients. Elevated IL-6 levels 
characterize the cytokine storm that occurs. 
TCZ is an anti-human monoclonal antibody 
directed against soluble and membrane-bound 
IL-6 receptors. TCZ works by binding to IL-6 
receptors (IL-6R) and preventing interactions 
with IL-6. This IL-6 elevation interrupts the 
downstream signal transduction cascade, 
which would release additional cytokines and 
chemokines. Therefore, it can reduce cytokine 
storms.33,34  
However, the IL-6 assessment was not 
performed in this study because it was limited 
to our center. Other markers described the 
evaluation of the TCZ effect. The marker that 
appears to be the most rapid improvement is 
CRP, whose expression of this gene is also 
mainly induced by IL-6. 23 Meanwhile, other 
markers tended to improve slowly, such as 
leucocytes on 12th days, NLR, ALC on the 
fifth day, LDH on 8th days, and ferritin 
fluctuated. Clinically, the patient's oxygen 
saturation has improved gradually, especially 
in 80% of surviving cases. 
 
CONCLUSION 
This study shows the response to 
tocilizumab in patients with severe to critical 
COVID-19. From 20 patients, 80% of patients 
showed improvement in clinical such as 
oxygen saturation, laboratory and chest X-
rays. CRP was a rapidly changing marker that 
can be checked immediately after 
administration to assess response to treatment. 
TCZ is an IL-6 inhibitor that can be 
considered a potential therapeutic agent in the 
management of COVID-19. However, this 
research was a descriptive and single-center 
study. We would suggest further research 
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